Cellular events and the pattern of p53 protein expression following cyclophosphamide-initiated cell death in various organs of developing embryo

Teratogenesis Carcinogenesis and Mutagenesis

Volumn 19, Issue 5, 1999, Pages 353-367

  Torchinsky, Arkady ^a   Ivnitsky, Irena ^a   Savion, Shoshana ^a   Shepshelovich, Jeana ^a   Gorivodsky, Marat ^a   Fein, Amos ^a   Carp, Howard ^a   Schwartz, Dov ^b   Frankel, Janne ^b   Rotter, Varda ^b   Toder, Vladimir ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Apoptosis; Cell cycle; Cyclophosphamide; P53; Teratogens

Indexed keywords

CYCLOPHOSPHAMIDE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL DEATH; EMBRYO DEVELOPMENT; FLOW CYTOMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TERATOGENESIS; TERATOLOGY;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL DEATH; CYCLOPHOSPHAMIDE; EMBRYONIC AND FETAL DEVELOPMENT; EXTREMITIES; FEMALE; HEAD; IN SITU NICK-END LABELING; LIVER; MICE; MICE, INBRED ICR; ORGAN SPECIFICITY; PREGNANCY; TERATOGENS; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MAMMALIA; MURINAE;

EID: 0032832531     PISSN: 02703211     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6866(1999)19:5<353::AID-TCM5>3.0.CO;2-0     Document Type: Article

References (25)

1. Sadler TW, Hunter ES III. Principles of abnormal development. Past, present and future. In: Kimmel CA, Buelke-Sam J, editors. Developmental toxicology, 2nd ed. New York: Raven Press; 1994. p 53-63.
2. Knudsen TV. Cell death. In: Kavlock RJ, Daston GP, editors. Drug toxicity in embryonic development I. Berlin, Heidelberg: Springer-Verlag; 1997. p 211-244.
3. Torchinsky A, Fein A, Toder V. Modulation of embryo sensitivity to teratogen by nonspecific intrauterine immunopotentiation. Toxicol Methods 1995;5:131-141.
4. Torchinsky A, Savion S, Gorivodsky M, Shepsheiovich J, Zaslavsky Z, Fein A, Toder V. Cyclophospharnide-induced teratogenesis in ICR mice: the role of apoptosis. Teratogen Carcinogen Mutagen 1995;15:179-190.
5. Wassermann K. Intragenomic heterogeneity of DNA damage formation and repair: a review of cellular responses to covalent drug DNA interaction. Crit Rev Toxicol 1994;24(4):281-323.
6. Lane DP. p53 Guardian of the genome. Nature 1992;358:15-16.
7. Wubah JA, Ibrahim MM, Gao X, Nguyen D, Pisano MM, Knudsen TB. Teratogen-induced eye defects mediated by 53-dependent apoptosis. Curr Biol 1996;6:60-69.
8. Nicol CJ, Harrison ML, Laposa RR, Gimelshtein I, Wells PG. A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. Nat Genet 1995;10:181-187.
9. Norimura T, Nomoto S, Katsuki M, Gondo Y, Kondo S. p53-dependent apoptosis suppresses radiation-induced teratogenesis. Nat Med 1996;2:577-580.
10. Moallem SA, Hales BF. The role of p53 and cell death by apoptosis and necrosis in 4-hydroperoxicyclophosphamide-induced limb malformations. Development 1998;125:3225-3234.
11. Midgley CA, Owens B, Brisco CV, Thomas DB, Lane DP, Hail PA. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci 1995;108:1843-1848.
12. Almog N, Rotter V. Involvement of p53 in cell differentiation and development. Biochem Biophys Acta 1997;1333:F1-27.
13. Toder V, Savion S, Gorivodsky M, Shepshelovich J, Zaslavsky Z, Fein A, Torchinsky A. Teratogen-induced apoptosis may be affected by immunopotentiation. J Reprod Immuno 1996;130:173-185.
14. Wise LD, Beck SL, Beltrame D, Beyer BK, Chahoud I, Clark RL, Clark R, Druga AM, Feuston MH, Gultin P, Henwood SM, Kimmel CA, Lindstrom P, Palmer AK, Petrere JA, Solomon HM, Yasuda M, York RG. Terminology of developmental abnormalities in common laboratory mammals. Teratology, 1997;55:249-292.
15. Antoni-Grinshtein R, Schwartz D, Rotter V. Accumulation of wild-type p53 protein upon γ-irradiation induces a G2 arrest-dependent immunoglobulin κ light chain gene expression. The EMBO J 1995;14:1392-1400.
16. Sokal RR, Rohlf FJ. Biometry, 3rd ed. New York: Freeman and Co.; 1995.
17. Louis JM, McFarland VW, May P, Mora PT. The phosphoprotein p53 is down-regulated post-transcriptionally during embryogenesis in vertebrates. Biochem Byophys Acta 1988;950:395-402.
18. Schmid P, Lorenz A, Hameister H, Montenarh M. Expression of p53 during mouse embryogenesis. Development 1991;113:857-865.
19. Chernoff NJ, Rogers M, Alles AJ, Zucker RM, Elstein KH, Massaro EJ, Sulik KK. Cell cycle alterations and cell death in cyclophosphamide teratogenesis. Teratogen Carcinogen Mutagen 1989;9:199-209.
20. Francis BM, Rogers JM, Sulik KK, Alles AJ, Elstein KH, Zucker RM, Massaro EJ, Rosen MB, Chernoff N. Cyclophosphamide teratogenesis: evidence for compensatory responses to induced cellular toxicity. Teratology 1990;42:473-482.
21. Little SA, Mirkes PE. Effects of 4-hydroperoxyceclophosphamide (4-OOH-CP) and 4-hydroperoxy-dechloroclophosphamide (4-OOH-deCLPH) on the cell cycle of post implantation rat embryos. Teratology 1992;45:163-173.
22. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell 1993;74:957-967.
23. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994,266:1821-1828.
24. Powers JF, Sladek NE. Cytotoxic activity relative to 4-hydrocyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide treated rats. Cancer Res 1983;43:1101-1106.
25. 6-alkylguanidine-DNA-alkyltransferase in response to ionizing radiation is p53 gene dose dependent. Oncogene 1996;12:693-697.